bpdo-1603
Nucleic acidexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Feb 3, 2020 (NCT04229927)
Timeline
Indications
Mechanism of action
- NEDD8-activating enzyme E1 regulatory subunitANTISENSE INHIBITOR
NAE1 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05804279 | Phase 1 | Dec 28, 2022 | Hyundai |
| NCT04229927 | Phase 3 | Feb 3, 2020 | Hyundai |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hyundai | For profit | 2 | 2 | 2 | 2020 |
1 organizations
Page 1 / 1